- Home
- OSUR vs DSGN Comparison
OSUR vs DSGN Comparison
Compare OSUR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- DSGN
- Stock Information
- Founded
- OSUR 2000
- DSGN 2017
- Country
- OSUR United States
- DSGN United States
- Employees
- OSUR N/A
- DSGN N/A
- Industry
- OSUR Medical/Dental Instruments
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- OSUR Health Care
- DSGN Health Care
- Exchange
- OSUR Nasdaq
- DSGN Nasdaq
- Market Cap
- OSUR 223.0M
- DSGN 224.8M
- IPO Year
- OSUR 1986
- DSGN 2021
- Fundamental
- Price
- OSUR $3.00
- DSGN $3.71
- Analyst Decision
- OSUR Hold
- DSGN Hold
- Analyst Count
- OSUR 1
- DSGN 1
- Target Price
- OSUR $3.00
- DSGN $4.00
- AVG Volume (30 Days)
- OSUR 804.6K
- DSGN 91.0K
- Earning Date
- OSUR 08-05-2025
- DSGN 08-04-2025
- Dividend Yield
- OSUR N/A
- DSGN N/A
- EPS Growth
- OSUR N/A
- DSGN N/A
- EPS
- OSUR N/A
- DSGN N/A
- Revenue
- OSUR $161,626,000.00
- DSGN N/A
- Revenue This Year
- OSUR N/A
- DSGN N/A
- Revenue Next Year
- OSUR $6.20
- DSGN N/A
- P/E Ratio
- OSUR N/A
- DSGN N/A
- Revenue Growth
- OSUR N/A
- DSGN N/A
- 52 Week Low
- OSUR $2.36
- DSGN $2.60
- 52 Week High
- OSUR $4.92
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- OSUR 54.60
- DSGN 47.78
- Support Level
- OSUR $2.78
- DSGN $3.66
- Resistance Level
- OSUR $3.03
- DSGN $3.84
- Average True Range (ATR)
- OSUR 0.13
- DSGN 0.25
- MACD
- OSUR 0.01
- DSGN -0.02
- Stochastic Oscillator
- OSUR 58.93
- DSGN 18.06
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.